Clinical Trials Browser

Completed × Breast Neoplasms, Male × Trastuzumab × Clear all

NCT00770809 2025-08-15

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Phase 3 Completed

305 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT03112590 2023-04-19

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Phase 1/2 Completed

51 enrolled 13 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Phase 2 Completed

122 enrolled 22 charts

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

NCT00085020 2020-08-03

GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu

Phase 1 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00820872 2019-10-21

Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer

Phase 2 Completed

30 enrolled 6 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00971737 2019-04-24

Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

63 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00847171 2018-09-26

Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

Phase 2 Completed

20 enrolled 6 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT02060253 2018-06-14

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Phase 1 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00331552 2017-07-26

Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

Phase 1/2 Completed

30 enrolled 13 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00482391 2017-05-12

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Phase 2 Completed

95 enrolled 7 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00093808 2017-03-06

Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

47 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00086957 2017-02-27

Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

Phase 1/2 Completed

31 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00182793 2017-02-23

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

Phase 2 Completed

32 enrolled 6 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00077376 2014-05-21

Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer

Phase 2 Completed

61 enrolled 12 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00006228 2013-10-08

Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00028535 2013-06-04

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

Phase 1 Completed

BreastGastrointestinalGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Male, Small Cell Lung Carcinoma

NCT00004074 2013-02-28

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Phase 1 Completed

BreastEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Thyroid Cancer, Papillary, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Vipoma, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gallbladder Neoplasms, Glucagonoma, Carcinoma, Hepatocellular, Insulinoma, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Parathyroid Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Somatostatinoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Gastrinoma, Pleural Effusion, Malignant, Endometrial Neoplasms, Adenocarcinoma, Follicular, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Carcinoma, Medullary, Breast Neoplasms, Male, Inflammatory Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT00005842 2013-02-11

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

Phase 1 Completed

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Thyroid Cancer, Papillary, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Vipoma, Esophageal Neoplasms, Gallbladder Neoplasms, Glucagonoma, Carcinoma, Hepatocellular, Insulinoma, Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Parathyroid Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Somatostatinoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Gastrinoma, Pleural Effusion, Malignant, Endometrial Neoplasms, Adenocarcinoma, Follicular, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Carcinoma, Medullary, Breast Neoplasms, Male, Meningeal Carcinomatosis, Inflammatory Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT00433407 2012-10-04

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

Phase NA Completed

BreastGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Breast Neoplasms, Male, Small Cell Lung Carcinoma

NCT00068757 2012-09-12

Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Phase 1 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00019812 2012-03-23

Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00301899 2012-03-08

Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male